Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery.

Michael Green,Nelson J. Chao,Saurabh Chhabra,Kelly Corbet,Cristina Gasparetto,Ari Horwitz,Zhiguo Li,Jagadish Kummetha Venkata,Gwynn D. Long,Alice S. Mims,David A. Rizzieri,Stefanie Sarantopoulos,Robert K. Stuart,Anthony D. Sung,Keith M. Sullivan,Luciano J. Costa,Mitchell E. Horwitz,Yubin Kang

Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery.

2016

Michael Green
Nelson J. Chao
Saurabh Chhabra
Kelly Corbet
Cristina Gasparetto
Ari Horwitz
Zhiguo Li
Jagadish Kummetha Venkata
Gwynn D. Long
Alice S. Mims
David A. Rizzieri
Stefanie Sarantopoulos
Robert K. Stuart
Anthony D. Sung
Keith M. Sullivan
Luciano J. Costa
Mitchell E. Horwitz
Yubin Kang

Background The binding of CXCR4 with its ligand (stromal-derived factor-1) maintains hematopoietic stem/progenitor cells (HSPCs) in a quiescent state. We hypothesized that blocking CXCR4/SDF-1 interaction after hematopoietic stem cell transplantation (HSCT) promotes hematopoiesis by inducing HSC proliferation.

Keywords:

Cancer research
Progenitor cell
CXCR4
Biology
Hematopoietic stem cell transplantation
CXCR4 antagonist
Immunology
Transplantation Conditioning
Haematopoiesis
Plerixafor
Myeloablative Agonist
Platelet Engraftment
Transplantation
Absolute neutrophil count
Internal medicine
Oncology
Neutrophil Engraftment

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations